The inclusion of exon 16 in mature protein 4.1R mRNA arises from a stage-specific splicing event that occurs during late erythroid development. We have shown that mouse erythroleukemia (MEL) cells reproduce this erythroid-specific splicing event upon induction of differentiation. We here found that this splicing event is regulated specifically in erythroleukemic cells that have the potential to differentiate and produce hemoglobin, regardless of the nature of the differentiation inducer. Knowing that dysregulated expression of spi-1/pu.1 and fli-1 oncogenes is involved in MEL cell differentiation arrest, we looked at their effect on exon 16 erythroid splicing. We found that exon 16 inclusion requires Spi-1/ PU.1 shutdown in MEL cells, and that enforced expression of Spi-1/PU.1 inhibits exon selection, regardless of the presence or absence of a chemical inducer. By contrast, endogenous overexpression or enforced expression of Fli-1 has no effect on exon selection. We further showed that Spi-1/PU.1 acts similarly on the endogenous and on a transfected exon 16, suggesting a promoterindependent effect of Spi-1/PU.1 on splicing regulation. This study provides the first evidence that Spi-1/PU.1 displays the unique property, not shared with Fli-1, to inhibit erythroid-specific pre-mRNA splicing in erythroleukemia cell context.
Introduction
Protein 4. 1R is an important structural component of the red cell skeleton, encoded by a single genomic locus, over 200 kb in length in human (Baklouti et al., 1997) . Previous studies have shown that inclusion of a 21 amino-acid sequence motif at the N-terminus of the 10 kDa spectrin/actin-binding (SAB) domain is required to promote cytoskeletal junctional complex stability (Horne et al., 1993; Discher et al., 1995) . It has also been documented that incorporation of exon 16 sequence encoding this motif in the mature mRNA occurs at a late stage of erythroid development ( Figure 1a , Chasis et al., 1993; Baklouti et al., 1996) . Studies of protein 4.1R expression in a variety of nonerythroid tissues have demonstrated the presence of multiple splicing pathways that result in subtle differential expression of alternatively spliced exons in the SAB region (Baklouti et al., 1997, and references therein) . Splicing of exon 16 is thus a highly specific and striking example of regulated alternative splicing. In a previous work, we used mouse erythroleukemia (MEL) cells to analyse the erythroid pattern of splicing of 4.1R pre-mRNA upon dimethylsulfoxide (DMSO)-induced differentiation. We showed that exon 16 is preferentially included in mature 4.1R mRNA in differentiating cells, and that the protein isoform bearing exon 16-encoding peptide is preferentially and rapidly recruited in the membrane (Baklouti et al., 1996) . More recently, we have developed in MEL cells a stable transfection system, which reproduces this regulated splicing pattern, using minigene constructs bearing exon 16. We showed that multiple cis-acting elements, within the exonic and close vicinity intronic sequences, contribute coordinately to exon skipping in predifferentiated cells, and to promote exon inclusion as the cells differentiate (Deguillien et al., 2001) .
MEL cells are derived from mice infected by either one of two variants of Friend virus complex: a replication-defective, spleen-focus-forming virus (SFFV) and a replication-competent Friend murine leukemia virus (F-MuLV) . Most of the SFFV-induced erythroleukemia cells (SFFV cells) are associated with activation of the spi-1/pu.1 gene through proviral insertion, leading to overexpression of the ETS family transcription factor Spi-1/PU.1 (Moreau-Gachelin et al., 1988) . In contrast, the spi-1/pu.1 gene is not rearranged in FMuLV cells. Instead, the provirus integration site is preferentially at fli-1, a gene encoding yet another member of the ETS family of transcription factors (Ben-David et al., 1991) . Interestingly, Fli-1 is also expressed in SFFV cells, due to the direct activation of the fli-1 gene by Spi-1/PU.1 (Starck et al., 1999) .
High expression of Spi-1/PU.1 is associated with cell differentiation arrest , and references therein). It has been established that DMSO treatment results in Spi-1/PU.1 downregulation, which in turn is required for terminal erythroid differentiation (Schuetze et al., 1992) . Consistently, enforced expression of Spi-1/PU.1 blocks cell differentiation (Rao et al., 1997; Yamada et al., 1997; Oikawa et al., 1999) . Similarly, overexpression of Fli-1 inhibits chemically induced terminal differentiation of MEL cells (Starck et al., 1999; Tamir et al., 1999) .
Spi-1/PU.1 appeared to affect pre-mRNA splicing (Hallier et al., 1996 (Hallier et al., , 1998 . More specifically, it has been shown that Spi-1/PU.1 interacts with p54 nrb , a protein similar to the splicing factor PSF (PTBassociated protein), and inhibits intron removal from an artificial pre-mRNA substrate in in vitro splicing reaction (Hallier et al., 1996) . Spi-1/PU.1 also interacts with TLS, and promotes the usage of a proximal 5' splice site, possibly by antagonizing TLS in intact cells (Hallier et al., 1998) .
Altogether, these findings prompted us to examine the erythroid splicing regulation in cells induced to terminal differentiation, under different culture systems, and to investigate the impact of Spi-1/PU.1 and Fli-1 expression on splicing in erythroleukemia cell context. We found that exon 16 inclusion in differentiating MEL cells does not result from a direct effect of the inducer, and is inhibited by Spi-1/PU.1, but not by Fli-1. These data were consistently supported by enforced overexpression experiments of either Spi-1/PU.1 or Fli-1 in MEL cells. Although both Spi-1/PU.1 and Fli-1 block erythroid terminal differentiation, this study emphasizes the fact that they might contribute to this block through different pathways, and display different effects on a particular erythroid terminal differentiation event.
On the other hand, our data further support the view that deregulation of a DNA-binding transcription factor can affect gene expression not only at the transcriptional level but also by acting on pre-mRNA splicing regulation.
Results
Splicing regulation of 4.1R pre-mRNA is associated with the potential of erythroleukemia cells to undergo terminal erythroid differentiation
We have previously shown that MEL cells can reproduce the splicing pattern of endogenous (Baklouti et al., 1996) and transfected (Deguillien et al., 2001) exon 16 of 4.1R pre-mRNA during erythroid terminal differentiation. As depicted in Figure 1b , exon 16 splicing was examined using semiquantitative reverse transcription-polymerase chain reaction (RT-PCR), and expressed as percentage of exon-bearing isoforms to total mature mRNA isoforms. In addition, the fraction of hemoglobin-producing cells was monitored to determine the percentage of cells undergoing terminal differentiation.
A recent work has shown that DMSO can alter premRNA splicing by interfering with the recruitment of splicing factors (Bolduc et al., 2001) . This observation led us to ask whether exon 16 inclusion in mature 4.1R Spi-1/PU.1 regulates erythroid pre-mRNA splicing O Théoleyre et al mRNA in DMSO-treated MEL cells could reflect such a direct effect of DMSO. To address this issue, we tested the effect of HMBA, a hybrid polar compound widely used to induce MEL cell erythroid differentiation. As shown in Figure 2 , we reproducibly found that HMBA and DMSO basically have the same incidence on splicing pattern switch from uninduced to induced cells. However, HMBA seems to be a better inducer of hemoglobin accumulation in the cells, whereas DMSO leads to slightly higher percentage of exon 16-containing isoforms, generated from the endogenous gene. These data suggest that exon 16 inclusion does not result from a direct effect of DMSO, but must be part of the erythroid differentiation program, activated by either of these chemicals. Consistently with previous data (Baklouti et al., 1996; Deguillien et al., 2001) , exon inclusion appears more prominent on transfected minigene transcripts than on endogenous transcripts, in both DMSO-and HMBAinduction experiments (Figure 2 ).
We then analysed the splicing event in the presence of the physiological erythroid inducer, erythropoietin (Epo), in either Epo-responsive or Epo-unresponsive cells. Hence, exon 16 splicing pattern was examined in Rauscher cell lines, as well as in two MEL cell lines: SKT6 and 745-A. SKT6 is an SFFV MEL cell type that has the potential to differentiate in response to Epo (Todokoro et al., 1987) , whereas the SFFV 745-A cells do not differentiate upon exposure to Epo. To ascertain that Epo potential activity is not altered in SFFV cell cultures, we performed a Northern blot analysis, using c-myc probe (not shown), and confirmed the early c-myc transcriptional activation in all three cell lines, as previously reported (Chern et al., 1991) . As expected, Epo appears to trigger hemoglobin synthesis in SKT6 and Rauscher cells, but not in 745-A cells (Figure 3 ). Splicing analysis showed a concomitant increase of exon 16-containing isoform in Epo-responsive cells, but not in 745-A cells. This finding suggests once again that exon 16-regulated splicing correlates with erythroid differentiation of SFFV cells, regardless of the component used to induce cell differentiation.
Spi-1/PU.1 but not Fli-1 affects exon 16 splicing regulation in MEL cells
To investigate the effect of Spi-1/PU.1 and Fli-1 expression on exon 16 splicing, we first compared the endogenous exon splicing pattern in SFFV and FMuLV cells, before and after exposure to chemical inducer. Both of these cell types express high levels of Fli-1, but differ in the expression of Spi-1/PU.1 (see Introduction). As shown in Figure 4 , a predifferentiated pattern of exon 16 inclusion is again observed in uninduced SFFV cells, whereas both F-MuLV cell lines, NN10 and IW32, express four to five times more of the isoform containing exon 16 in the absence of DMSO or HMBA. This pattern, with high level of exon 16 inclusion, remains unchanged in F-MuLV cells in the presence of either of the two inducers. However, as expected, the hemoglobin production is activated only in induced SFFV cells. These observations suggest that splicing regulation of exon 16 is not correlated with Fli-1 expression in MEL cells, but rather depends on Spi-1/ PU.1 shutdown.
Fli-1 was then constitutively overexpressed in SFFV cells upon transfection with pEF-LAC-Fli ( Figure 5 ), or pcDNA3-Fli (not shown). DMSO treatment leads to downregulation of the endogenous fli-1 gene, through the Spi-1/PU.1-Fli-1 signaling cascade (Starck et al., We next asked whether the DMSO-induced Spi-1/ PU.1 downregulation is required for the splicing event to occur. To address this issue, Spi-1/PU.1 was constitutively overexpressed from stably transfected cDNA in SFFV 745A cells. Two independent clones were isolated and tested for Spi-1/PU.1 high-level expression by Western blot. Representative results from a single clone are illustrated in Figure 6 . The forced expression of Spi-1/PU.1 results in a partial but significant inhibition of terminal differentiation, as assessed by hemoglobin expression in Spi þ cells, vs mock cells (Figure 6 ). Analysis of exon 16 splicing revealed a concomitant repression of exon inclusion in Spi þ cells after induction, whereas transfection with the empty vector in mock cells did not affect splicing regulation in induced cells. Thus, it clearly appears from this set of experiments that downregulation of Spi-1/ PU.1 is a key event that is required for exon splicing regulation.
To examine whether Spi-1/PU.1 expression is sufficient to modulate exon inclusion in a DMSO-or HMBA-independent manner, we expressed Spi-1/PU.1 in F-MuLV-NN10, from the same pHook-Spi-1 vector construct used in the previous set of experiments. Since F-MuLV cells virtually do not express Spi-1/PU.1, we followed exon splicing in polyclonal cell population in this particular set of experiments. Spi-1/PU.1-enforced expression was assessed by Western blot in stably transfected cells. As shown in Figure 7 , expression of Spi-1/PU.1 alone in F-MuLV cells results in significant decrease of exon inclusion. Exposure to either DMSO or HMBA did not change the exon splicing status in either the mock cells or Spi þ cells. In all cases, that is both in mock and Spi þ cells, before and after induction, Fli-1 expression was high and hemoglobin expression remained silent.
Altogether, these data indicate that Spi-1/PU.1 downregulation is critically required for exon 16 inclusion in response to chemical inducers. These data also show that exon inclusion is inhibited by Spi-1/PU.1 Spi-1/PU.1 expression regulates exon splicing in a promoter-independent manner
We asked whether Spi-1/PU.1 exerts its inhibitory effect directly by titrating nuclear splicing factors, or through a transcriptional regulation mechanism. We looked if Spi-1/PU.1 downregulation in differentiating MEL cells affects the transcription level of the endogenous 4.1R gene and the WT minigene, an exon 16-containing minigene driven by CMV promoter (Deguillien et al., 2001) ; see Materials and methods). Consistent with previous data obtained by RNase protection assay (Baklouti et al., 1996) , real-time RT-PCR quantification clearly showed an increase of the transcriptional activity of the endogenous 4.1R gene upon cell differentiation (Figure 8a ). By contrast, the transcriptional level of the transfected minigene is not affected along with Spi-1/ PU.1 decrease in differentiating cells (Figure 8a ). We then asked whether Spi-1/PU.1 have the same splicing inhibitory effect on exon 16-containing pre-mRNA templates driven by different promoters. To approach this issue, we overexpressed Spi-1/PU.1 in SFFV cells stably transfected with WT construct. As shown in Figure 8b , constitutive expression of Spi-1/PU.1 resulted in a decrease of exon selection from the transfected premRNA, similar to the decrease observed for the endogenous pre-mRNA. Again hemoglobin expression was significantly inhibited in Spi þ cells upon exposure to DMSO or HMBA. Although we cannot rule out a differential recruitment of splicing factors at 4.1R promoter before and after cell induction, these data suggest that exon inclusion associated with Spi-1/PU.1 downregulation in MEL differentiating cells occurs in a promoter-independent manner.
Discussion
Inclusion of exon 16 at the mature 4.1R mRNA occurs at a late stage of normal erythroid development, and has a major impact on proper assembly and functional properties of 4.1R at the mature red cell membrane. Indeed, it has been shown that 4.1R deficiency or the only defect of the 10 kDa SAB domain affects the stability of the spectrin-actin junctional complex Marchesi et al., 1990; Lorenzo et al., 1994; Maillet et al., 1999) .
Splicing of exon 16 in differentiating MEL cells is regulated within an erythroid terminal differentiation program
In our previous works (Baklouti et al., 1996; Deguillien et al., 2001) , we used DMSO to commit MEL cells to late erythroid differentiation. DMSO is a polar solvent that induces or blocks differentiation and apoptosis of a variety of cell lines. It can also affect different aspects of mRNA metabolism, including transcription, maturation, translation and stability, leading to quantitative and structural (alternative splicing) changes of a variety of transcripts (Bolduc et al., 2001 , and references therein). Whether these effects result from a direct interference of DMSO with one step or the other of mRNA metabolism is an issue that has just begun to be addressed. Hence, it has recently been shown that DMSO activates splice site selection and enhances SR protein activity in HeLa extracts (Bolduc et al., 2001 Erythroid-specific splicing of 4.1R pre-mRNA is affected by Spi-1/PU.1, but not by Fli-1
This finding raised the questions as to whether and how this erythroid-specific splicing event is coordinated with other erythroid-specific events, such as hemoglobin synthesis. Knowing that both Spi-1/PU.1 and Fli-1 are involved in the inhibition of hemoglobin production in MEL cells, we asked whether they both also inhibit the erythroid-specific splicing. Data presented in this study clearly establish that only Spi-1/PU.1 has an effect on erythroid splicing regulation. Either of the DMSO or HMBA chemical induction leads to Fli-1 downregulation in SFFV cells (Figure 5a ). However, substantial amount of Fli-1 is expressed in the cells after induction. It is therefore possible that additional Fli-1 expression does not have an effect on the splicing event, but seems to be required to efficiently inhibit hemoglobin production (Figure 5b ). Moreover, this study highlights the fact that two events of the erythroid terminal differentiation program, that is hemoglobin production and exon 16-regulated splicing, can be uncoupled in MEL cell system, based on two observations: (i) high level of exon 16-containing isoform is observed in native F-MuLV cells, which already express high levels of Fli-1, but do not produce hemoglobin; and (ii) constitutive overexpression of either Spi-1/PU.1 or Fli-1 through stable transfection in SFFV cells inhibits hemoglobin synthesis, but only that of Spi-1/PU.1 affects the regulated splicing. These findings lead to the conclusion that the oncogenic protein Spi-1/PU.1 displays the unique property, not shared with the other ETS oncogenic protein Fli-1, to inhibit erythroid-specific splicing.
Spi-1/PU.1 decline is required for erythroid differentiation (Schuetze et al., 1992) ; this downregulation may be a very early step in a differentiation program, including changes in c-myc and c-myb expression (Rao et al., 1997) . In fact, dysregulated expression of any of the proto-oncogenes c-myc, c-myb and spi-1/pu.1pre-cludes MEL cell differentiation (Rao et al., 1997, and included references) . Several reports have shown that Spi-1/PU.1 inhibits erythroid cell differentiation, probably through different pathways. Spi-1/PU.1 and the major erythroid transcription factor GATA-1 cross antagonize one another through direct interaction (Rekhtman et al., 1999; Zhang et al., 1999 Zhang et al., , 2000 Nerlov et al., 2000) . On the other hand, Spi-1/PU.1 inhibits CBP-mediated acetylation of erythroid transcription factors GATA-1, EKLF and NF-E2 (Hong et al., 2002) . Both inhibitory effects of Spi-1/PU.1 are thought to contribute to erythroid differentiation arrest and to malignant transformation. Data presented here and elsewhere (Baklouti et al., 1996) , demonstrated that Spi-1/PU.1 downregulation is concomitant with an increase of 4.1R mRNA accumulation. Whether 4.1R transcriptional regulation is directly associated with the abovementioned crossantagonisms involving Spi-1/PU.1 remains to be investigated.
In addition to these interactions at the transcriptional level, it has been shown that Spi-1/PU.1 interferes with pre-mRNA splicing of artificial transcripts in vitro and in vivo, and that this effect involves Spi-1/PU.1 DNAbinding domain (Hallier et al., 1996 (Hallier et al., , 1998 . We looked if Spi-1/PU.1 directly binds to exon 16 pre-mRNA context in electrophoretic mobility shift assays (EMSA) and UV crosslinking experiments, using GST-Spi-1/PU.1 and labeled RNA templates (not shown). These experiments were all consistent with the absence of direct binding of Spi-1/PU.1 to these specific sequences. Spi-1/PU.1 seems to bind preferentially homoribopoly(G) sequence (Hallier et al., 1996) ; it is therefore not surprising that the binding assays showed no direct interaction with exon 16 RNA template, which does not contain over three residue poly(G) stretch sequences (Deguillien et al., 2001) . Altogether, these data suggest that Spi-1/PU.1 inhibition effect does not involve a direct interaction with neither the exon sequences, nor the close intron sequences.
It has been proposed that Spi-1/PU.1 would interfere with splicing by sequestring splicing factors (Hallier et al., 1996 (Hallier et al., , 1998 . Whether recruitment of splicing factors by Spi-1/PU.1 occurs at the site of transcription, and would therefore be modulated by the promoter, remains a debated issue that is worth exploring. Our finding that Spi-1/PU.1 inhibits in a similar fashion both endogenous and transfected 4.1R pre-mRNA templates tend to support the view that Spi-1/PU.1 would act in a promoter-independent manner. However, it is equally possible that Spi-1/PU.1 may modulate the levels of splicing factors by regulating their expression at the transcription level. Furthermore, binding assays (data not shown) suggest that Spi-1/PU.1 inhibition effect does not involve a direct binding to the mRNA molecule, but might rather involve a protein-protein interaction. Such an interaction between a transcription factor and the splicing machinary has been described (Davies et al., 1998) . In this work, and references therein, it has been shown that the Wilms' tumor suppressor gene wt1, which encodes a zinc-finger transcription factor implicated in the regulation of a number of genes, also associates with the spliceosome components and directly interacts with the essential splicing factor U2AF65.
To our knowledge, regulated exon 16 splicing is the first example of an endogenous erythroid-specific splicing affected by Spi-1/PU.1 expression in erythroleukemia cell context. We believe that transformed cell lines remain a useful model system to approach the mechanism of alternative splicing in malignant cell context, and to ultimatly better understand its regulation in normal cells. In that respect, the differential effects of Spi-1/ PU.1 and Fli-1 on exon 16 inclusion could help to dissect the molecular mechanism involved in this splicing event in erythroleukemia cell context. We believe that this mechanism would necessarily cross the normal erythrocytic differentiation program, and therefore allow to identify key regulators within that program.
Materials and methods

Plasmid constructs
The minigene construct containing exon 16, designated WT construct, has been described and used previously (Deguillien et al., 2001) . Briefly, exon 16 and B300 nt intronic sequences on both sides were inserted in a splicing cassette p(13,17)/CMV containing the two adjacent constitutive exons, exons 13 and 17, with their downstream and upstream flanking intron sequences, respectively. The following recombinant plasmids were used to analyse the overexpression effects of spi-1/ pu.1and fli-1 in MEL cells: Spi-1/PU.1 and Fli-1 overexpression was assessed from the previously described plasmid constructs pHOOK-Spi-1 and pEF-LAC-Fli, respectively (Starck et al., 1999) . The pcDNA3-Fli construct was obtained by inserting a 1.7 kb fragment containing Fli-1 encoding sequence into pcDNA3 vector (Invitrogen, Cergy Pontoise, France), at the NotI site, under the transcriptional control of CMV promoter.
Cell culture, induction and transfection
In most of the experiments described here, we used the subclone 745-A, which is an SFFV cell line. IW32 and NN10 are derived from F-MuLV-induced erythroleukemias. SKT6 is an Epo-responsive SFFV-derived cell line (Todokoro et al., 1987) . Two Rauscher cell lines were tested; they derive from leukemic mice infected with Rauscher virus (Chern et al., 1991; Hanspal et al., 1992) .
Cells were cultured in suspension in DMEM supplemented with 10% FBS and induced to erythroid differentiation as previously described (Deguillien et al., 2001) . For stable expression, proliferative cells (2 Â 10 5 cells) were transfected prior to DMSO induction with 500 ng of plasmid DNA using LipofectAminet reagent (Invitrogen) in 24-well tissue culture plates, according to the manufacturer's procedure. Cells were cultured in complete DMEM medium containing 800 mg G-418/ml, or 400 mg zeocin/ml, to select stably transfected clones. MEL cell induction was performed in the same media for 5 days, in the presence of 1.8% DMSO, 5 mM HMBA or 2 U/ml Epo. Induction of Rauscher cells was also performed for 5 days, using 0.8% DMSO, 1 mM HMBA or 2 U/ml Epo.
Semiquantitative RT-PCR
Total RNA was extracted from cell lysates using the Trizol reagent (Invitrogen), according to the supplier's protocol. The RT-PCR experiments were performed as previously detailed (Deguillien et al., 2001) . Different sets of primers were used to distinguish between endogenous murine 4.1R mRNA and mRNA derived from the human minigene. The quantitative PCR amplification was carried out for different cycle numbers, and the PCR products were quantified as previously described (Deguillien et al., 2001) . Quantification measurements were obtained using ImageQuantMac v1.2 software.
Real-time quantitative RT-PCR
One mg of total RNA was reverse transcribed in 20 ml by using Superscript II RT, in the presence of 0.25 mM random hexamers and 0.05 mM specific antisense primers. These latter are used as reverse primers at the PCR step (see below). After adding 15 ml of water and mixing, 5 ml aliquots were used for each PCR amplification. Each PCR reaction was optimized to ensure that a single band of the appropriate length was amplified and that no bands corresponding to genomic DNA amplification or primer-dimer pairs were present. Real-time PCR for 4.1R and GAPDH was carried out using the QuantiTect SYBR Green System (Qiagen) and LightCycler apparatus (Roche), according to the manufacturers' specifications. The PCR reaction mixture contained 0.5 mM of each of the primers for endogenous 4.1R (forward: CTTTTGGAA-GAAGACTACTTTGGT, reverse: ATGTCTTCTGTTAATT GTGCTGGGTC); transfected 4.1R (forward: AAGGCGGC CGCCTAGATGCCTCTGCT, reverse: GCGAATTCATGC TTCTGTGGGCTCTGGC); or GAPDH (forward: CAAC-GACCCCTTCATTGACCTC, reverse: AGAGCGAGGAC CTTCTACCACTA). RNA samples were obtained from four different induction experiments. GAPDH was used as endogenous control. The thermal cycler conditions were carried out for 45 cycles. Data were analysed using Sequence Detection System software version 1.6.3. Results were obtained as CT (Threshold cycle) values, which is inversely proportional to the starting template copy number. The difference in CT values between the 4.1R and GAPDH reactions in uninduced cells was converted into 4.1R expression units (4.1R/GAPDH ¼ 1), and used as a standard.
Western blot
Cultured cells were pelletted and lysed in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 20 mM EDTA, 1% Triton Spi-1/PU.1 regulates erythroid pre-mRNA splicing O Théoleyre et al X-100, 1% sodium deoxycholate, 0.1% SDS), containing protease inhibitor cocktail 'Complete Mini, EDTA free' (Roche, Meylan, France), as recommended by the supplier. In all, 10-20 mg of proteins were resolved on 9% SDS-PAGE, and blotted onto nitrocellulose membranes. Transferred proteins were then visualized by soaking the membranes in Ponceau Red (Sigma, Saint-Quentin Fallavier, France) for 5 min. Two specific antibodies were used to probe the transferred proteins: an anti-Spi-1/PU.1 antibody (Delgado et al., 1994) and an anti-Fli-1 antibody sc-356 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). The immunoreactive proteins were revealed using ECL þ enhanced chemiluminescence detection kit (Amersham Biosciences AB), according to the manufacturer's protocol. A monoclonal antibody directed against mouse -actin (Chemicon International, Temecula, CA, USA) was used to standardize Spi-1/ PU.1 and Fli-1 signals.
Abbreviations DMSO, dimethylsulfoxide; EMSA, electrophoretic mobility shift assay; Epo, erythropoietin; F-MuLV, Friend murine leukemia virus; GST, glutathione-S-transferase; HMBA, hexamethylene-bisacetamide; MEL, mouse erythroleukemia; SAB, spectrin/actin-binding; SFFV, spleen focus-forming virus.
